Dr. Reddy's Laboratories gained 1.3% to Rs 5406.70 after the drug major announced the launch of febuxostat tablets in the US market.
Febuxostat tablets are a therapeutic equivalent generic version of Uloric (febuxostat) tablets approved by the U.S. Food and Drug Administration (USFDA).The Uloric brand and generic had US sales of approximately $108 million MAT for the most recent twelve months ending in October 2020 according to IQVIA Health.
Dr. Reddy's febuxostat tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets.
Dr. Reddy's Laboratories is an integrated pharmaceutical company. On a consolidated basis, Dr Reddy's Laboratories' net profit dropped 30.30% to Rs 771.80 crore on 2% increase in net sales to Rs 4,896.70 crore in Q2 September 2020 over Q2 September 2019.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app